Skip to content

Selective Laser Trabeculoplasty After Failed Phacoemulsification With Eximer Laser Trabeculectomy

Effectiveness of Selective Laser Trabeculoplasty (SLT) After Failed Phacoemulsification Cataract Extraction Combined With Eximer Laser Trabeculectomy (Phaco-ELT) in Open Angle Glaucoma and Ocular Hypertension

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02434250
Acronym
SLT
Enrollment
203
Registered
2015-05-05
Start date
2015-05-31
Completion date
2016-11-30
Last updated
2017-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Ocular Hypertension, Open Angle Glaucoma

Keywords

Open angle glaucoma, Ocular hypertension, Cataract, Selective Laser Trabeculoplasty, Eximer Laser Trabeculectomy, Phacoemulsification Cataract Extraction

Brief summary

The aim of this study is to evaluate the efficacy of selective laser trabeculoplasty after a prior failed phacoemulsification and Eximer Laser Trabeculectomy.

Detailed description

This study evaluates the efficacy of selective laser trabeculoplasty after a failed combined procedure of phacoemulsification cataract extraction with intraocular lens implantation plus Eximer Laser Trabeculectomy in open angle glaucoma or ocular hypertension. The success of SLT will be determined by the intraocular pressure and number of hypotensive drugs.

Interventions

PROCEDURESelective Laser Trabeculoplasty

Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* diagnosis of open angle glaucoma or ocular hypertension * and diagnosis of cataract

Exclusion criteria

* diagnosis of angle closure glaucoma * any optic neuropathy other than glaucoma

Design outcomes

Primary

MeasureTime frameDescription
Efficacy intraocular pressuret0 and t=12 monthEfficacy as measured by decrease in intraocular pressure from baseline
Efficacy medicationt0 and t=12 monthas measured by decrease in number of used hypotensive medications

Secondary

MeasureTime frameDescription
Efficacy visual acuityt0 and t=12 monthEfficacy as increase in best corrected visual acuity

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026